

TABLE OF CONTENTS

	Page Number
LIST OF TABLES	v
LIST OF APPENDICES	vii
LIST OF ACRONYMS AND ABBREVIATIONS	ix
ACKNOWLEDGEMENTS	xii
PREFACE	P-1
EXECUTIVE SUMMARY	ES-1
1.0 Introduction and Rationale for the Use of <i>In Vitro</i> ER TA Assays.....	1-1
1.1 Introduction	1-1
1.1.1 Historical Background of <i>In Vitro</i> Endocrine Disruptor Assays and Rationale for Their Development.....	1-1
1.1.2 Prior or Proposed Peer Reviews of <i>In Vitro</i> ER TA Assays	1-5
1.2 Scientific Basis for the Proposed Tier 1 <i>In Vitro</i> ER TA Assays.....	1-5
1.2.1 Purpose for Using <i>In Vitro</i> ER TA Assays.....	1-5
1.2.2 Development of <i>In Vitro</i> ER TA Assays: Historical Background ..	1-5
1.2.3 Mechanistic Basis of <i>In Vitro</i> ER TA Assays	1-9
1.2.4 Relationship of Mechanisms of Action in the <i>In Vitro</i> ER TA Assay Compared to the Species of Interest	1-11
1.3 Intended Uses of the Proposed <i>In Vitro</i> ER TA Assays.....	1-11
1.3.1 Validation of <i>In Vitro</i> ER TA Assays	1-11
1.3.2 Where Can <i>In Vitro</i> ER TA Assays Substitute, Replace, or Complement Existing Methods?	1-12
1.3.3 Similarities and Differences with Currently Used Methods	1-13
1.3.4 Role of <i>In Vitro</i> ER TA Assays in Hazard Assessment	1-13
1.3.5 Intended Range of Substances Amenable to the <i>In Vitro</i> ER TA Assay and/or Limits of the <i>In Vitro</i> ER TA Assay	1-14
1.4 Search Strategy and Selection of Citations for the <i>In Vitro</i> ER TA BRD ...	1-15
2.0 Methods for <i>In Vitro</i> ER TA Assays	2-1
2.1 Introduction	2-1
2.2 <i>In Vitro</i> Mammalian Cell ER TA Reporter Gene Assays	2-9

2.2.1	Expression and Reporter Gene Constructs	2-9
2.2.2	Stably and Transiently Transfected Cell Lines	2-10
2.2.3	<i>In Vitro</i> Mammalian Cell ER TA Assays with a Reporter Gene ..	2-10
2.3	Yeast Cell ER TA Reporter Gene Assays	2-12
2.3.1	Expression and Reporter Gene Constructs	2-12
2.3.2	Yeast Cell ER TA Assays with a Reporter Gene	2-12
2.4	<i>In Vitro</i> Mammalian Cell ER TA Assays Using Growth as an Endpoint	2-13
3.0	Characterization of Substances Tested in <i>In Vitro</i> ER TA Assays	3-1
3.1	Introduction	3-1
3.2	Rationale for Selection of Substances/Products Tested in <i>In Vitro</i> ER TA Assays	3-1
3.3	Chemical and Product Classes Tested.....	3-2
4.0	Reference Data	4-1
5.0	Data on <i>In Vitro</i> ER TA Assays	5-1
5.1	Introduction	5-1
5.2	Availability of Detailed <i>In Vitro</i> ER TA Protocols.....	5-1
5.3	Availability of <i>In Vitro</i> ER TA Data.....	5-2
5.4	<i>In Vitro</i> ER TA Results for Individual Substances	5-4
5.5	Use of Coded Chemicals and Compliance with Good Laboratory Practice (GLP) Guidelines	5-5
6.0	<i>In Vitro</i> ER TA Test Method Performance Assessment	6-1
6.1	Introduction	6-1
6.2	Quantitative Assessment of Assay Performance.....	6-1
6.3	Qualitative Assessment of Assay Performance.....	6-2
6.4	Performance of <i>In Vitro</i> ER TA Assays.....	6-7
6.5	Strengths and Limitations of <i>In Vitro</i> ER TA Assays.....	6-9
6.6	Summary and Conclusions and Recommendations	6-11
7.0	<i>In Vitro</i> ER TA Test Method Reliability Assessment.....	7-1
7.1	Introduction	7-1
7.2	Assessment of <i>In Vitro</i> ER TA Assay Reliability	7-1
7.3	Summary, Conclusions and Recommendations	7-12

8.0	Quality of Data Reviewed	8-1
8.1	Extent of Adherence to GLP Guidelines.....	8-1
8.2	Assessment of Data Quality	8-1
8.3	Quality Control Audit.....	8-2
9.0	Other Scientific Reports and Reviews.....	9-1
9.1	Availability of Other <i>In Vitro</i> ER TA Data.....	9-1
9.2	Conclusions from Other Scientific Reviews of <i>In Vitro</i> ER TA Methods.....	9-1
9.2.1	1996 Endocrine Disruptor Screening Methods Workshop	9-2
9.2.2	1997 Workshop on Screening Methods for Detecting Potential (Anti-) Estrogenic/Androgenic Chemicals in Wildlife	9-4
10.0	Animal Welfare Considerations	10-1
10.1	Refinement, Reduction, and Replacement Considerations	10-1
10.2	Use of Animals in <i>In Vitro</i> ER TA Assays	10-1
11.0	Practical Considerations	11-1
11.1	Test Method Transferability.....	11-1
11.1.1	Facilities and Major Fixed Equipment.....	11-1
11.2	Training Considerations	11-2
11.3	Estimated Cost and Time Considerations	11-2
12.0	Minimum Procedural Standards for <i>In Vitro</i> ER TA Assays and Recommended Substances for Use in Validation Studies.....	12-1
12.1	Introduction	12-1
12.2	Minimum Procedural Standards.....	12-1
12.2.1	Transcriptional Activation of the Reference Estrogen.....	12-1
12.2.2	Reference Estrogen.....	12-2
12.2.3	Preparation of Test Substances.....	12-2
12.2.4	Concentration Range of Test Substances	12-2
12.2.5	Solvent and Positive Controls	12-3
12.2.6	Within-Test Replicates	12-3
12.2.7	Dose Spacing.....	12-4
12.2.8	Data Analysis	12-4
12.2.9	Assay Acceptance Criteria	12-5

12.2.10	Evaluation and Interpretation of Results	12-5
12.2.11	Test Report	12-5
12.2.12	Replicate Studies	12-7
12.3	Standardization of <i>In Vitro</i> ER TA Assays for Validation.....	12-7
12.4	List of Recommended Substances for Validation of <i>In Vitro</i> ER TA Assays.....	12-8
12.5	Summary and Conclusions.....	12-11
13.0	References	13-1
14.0	Glossary.....	14-1

LIST OF TABLES

	Page Number
Table 2-1 <i>In Vitro</i> Yeast ER TA Reporter Gene Studies (Arranged by Strain)	2-2
Table 2-2 <i>In Vitro</i> Mammalian Cell ER TA Reporter Gene Studies (Arranged by Cell Line).....	2-3
Table 2-3 <i>In Vitro</i> Mammalian Cell ER TA Cell Proliferation Studies (Arranged by Cell Line).....	2-6
Table 3-1 Major Chemical Classes Tested in <i>In Vitro</i> ER TA Assays.....	3-3
Table 3-2 Major Product Classes Tested in <i>In Vitro</i> ER TA Assays.....	3-4
Table 5-1 Substances Tested in Five or More <i>In Vitro</i> Mammalian Cell or Yeast ER TA Reporter Gene Assays.....	5-6
Table 5-2 Substances Tested in Two or More <i>In Vitro</i> ER TA Cell Proliferation Assays.....	5-7
Table 6-1 Number of Substances Tested in Multiple <i>In Vitro</i> Mammalian Cell/Yeast ER TA Reporter Gene Assays.....	6-3
Table 6-2 Number of Substances Tested in Multiple <i>In Vitro</i> ER TA Cell Proliferation Assays	6-4
Table 6-3 Characteristics of Cells Used in <i>In Vitro</i> ER TA Assays.....	6-4
Table 6-4 Concordance of <i>In Vitro</i> ER TA Agonism Assays.....	6-6
Table 6-5 Concordance of <i>In Vitro</i> ER TA Antagonism Assays.....	6-7
Table 7-1 Median EC ₅₀ Values for Substances Tested for Agonism Activity in <i>In Vitro</i> ER TA Reporter Gene and Cell Proliferation Assays.....	7-2
Table 7-2 Comparison of Median EC ₅₀ Values (μM) for Substances Tested for Agonism Activity in <i>In Vitro</i> Mammalian and Yeast ER TA Reporter Gene and Cell Proliferation Assays.....	7-8
Table 7-3 EC ₅₀ Values of Substances Tested in the Same Assay in the Same Laboratory or the Same Assay in Different Laboratories	7-9
Table 11-1 Comparison of Estimated Costs, Time, and Special Equipment Needs for Different <i>In Vitro</i> ER Reporter Gene and Cell Proliferation Assays.....	11-3

Table 12-1	List of Substances Recommended for Validation of <i>In Vitro</i> ER TA	
	Assays for Agonism	12-9
Table 12-2	List of Substances Recommended for Validation of <i>In Vitro</i> ER TA	
	Assays for Antagonism	12-10

LIST OF APPENDICES

	Page Number
Appendix A Methods for <i>In Vitro</i> ER TA Assays.....	A-1
A1 ER TA Reporter Gene Assays Using MCF-7 Cells	A1-1
A2 ER TA Reporter Gene Assays Using Various Mammalian Cells.....	A2-1
A3 ER TA Cell Proliferation Assays	A3-1
A4 ER TA Reporter Gene Assays Using Yeast Cells.....	A4-1
Appendix B <i>In Vitro</i> ER TA Assay Protocols	B-1
B1 Protocol for HepG2 Cells + Receptor + Reporter and/or -gal Plasmids for Use in Steroid Hormone Receptor Assays (Provided by Dr. Kevin Gaido, CIIT Centers for Health Research, Research Triangle Park, NC, USA).....	B1-1
B2 Protocol for Chimeric ER -Mediated Reporter Gene Expression in MCF-7 Cells (Provided by Dr. Timothy Zacharewski, Dept. of Biochemistry, Michigan State University, Lansing, MI, USA)	B2-1
B3 Development of new reporter gene assay systems for screening Endocrine Disrupters (Provided by Drs. Mitsuru Iida and Teruhisa Kato, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan)	B3-1
B4 Development of stably transfected cell lines to screen Endocrine Disrupters (Provided by Drs. Mitsuru Iida and Teruhisa Kato, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan).....	B4-1
B5 Technical Perspective on the U.S. EPA Endocrine Disruptor Screening Program: <i>In Vitro</i> EDSTAC Guideline Protocols (Provided by Dr. Grantley Charles, Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, MI, USA, and Dr. William Kelce, Pharmacia Corporation, Kalamazoo, MI, USA).....	B5-1

B6	Lyticase-based cell lysis protocol of -Galactosidase assay for 96 well plates (Provided by Dr. Rémy Le Guével of the Université de Rennes, Rennes, France)	B6-1
B7	Protocol for High-Throughput System for Screening Estrogen-Like Chemicals (Provided by Dr. George C. Clark, Xenobiotic Detection Systems, Inc., Durham, NC, USA).....	B7-1
B8	Protocol for the MVLN Assay (Provided by Dr. Thomas E. Wiese, Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, and Dept. of Environmental Health Sciences, Tulane University, New Orleans, LA, USA)	B8-1
Appendix C	Chemical and Product Class Information for the Substances Tested in ER TA Assays	C-1
Appendix D	Substances Tested in the <i>In Vitro</i> ER TA Assays	D-1
D1	Data Sorted by Chemical Name and Assay.....	D1-1
D2	References	D2-1
Appendix E	Responses of Substances Tested in at Least Two Different Types of <i>In Vitro</i> ER TA Assays.....	E-1
Appendix F	Substances Tested in Different <i>In Vitro</i> ER TA Assays by the Same Investigator.....	F-1

LIST OF ACRONYMS AND ABBREVIATIONS

AF	Activation function
ANOVA	Analysis of variance
AR	Androgen receptor
ATP	Adenosine triphosphate
β -gal	Gene for β -galactosidase
BRD	Background Review Document
CASRN	Chemical Abstracts Service Registry Number
CAT	Chloramphenicol acetyl transferase
cDNA	Complementary deoxyribonucleic acid
CDTA	<i>trans</i> -1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid
CHO	Chinese hamster ovary
CMA	Chemical Manufacturers Association
CoA	Co-enzyme A
CP	Cell proliferation
CRGP	Chlorophenol red-b-D-galactopyranoside
CUP1	Copper-responsive yeast metallothionein
CYC1	Iso-1-cytochrome C promoter
DDT	Dichlorodiphenyltrichloroethane
DEAE	2-(Diethylamino)ethyl
def	Ligand binding domain of the estrogen receptor
DMSO	Dimethyl sulfoxide
EC ₅₀	Half-maximal effective concentration
EDSP	Endocrine Disruptor Screening Program
EDSTAC	Endocrine Disruptor Screening and Testing Advisory Committee
EPA	Environmental Protection Agency
ER	Estrogen receptor
ER	Estrogen receptor alpha
ER	Estrogen receptor beta
ERE	Estrogen response element

FBS	Fetal bovine serum
FIFRA	Federal Insecticide, Fungicide and Rodenticide Act
FFDCA	Federal Food, Drug, & Cosmetic Act
FQPA	Food Quality Protection Act
FR	<i>Federal Register</i>
GLP	Good Laboratory Practices
GR	Glucocorticoid receptor
hER	Human estrogen receptor
HPTE	2,2-Bis-(<i>p</i> -chlorophenyl)-1,1,1-trichloroethane
HRE	Hormone responsive elements
IC ₅₀	Concentration of the test substance inhibiting the reference estrogen response by 50%
ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods
<i>luc</i>	Luciferase reporter gene
µL	Microliter
µM	Micromolar
mER	Mouse estrogen receptor
mM	Millimolar
MMTV	Mouse mammary tumor virus
mRNA	Messenger RNA
NAS	National Academy of Sciences
NICEATM	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods
ng	Nanogram
nm	Nanometer
nM	Nanomolar
OD	Optical density
OECD	Organisation for Economic Co-operation and Development
OPNG	<i>o</i> -Nitrophenylgalactoside
PCB	Polychlorinated biphenyls

pgk	Phosphoglycerate kinase
pM	Picomolar
QC	Quality control
QSAR	Quantitative structure activity relationship
r	Rat
RPE	Relative proliferative effect
RPP	Relative proliferative potency
rt	Rainbow trout
SAB	Science Advisory Board
SAP	Scientific Advisory Panel
SDS	Sodium dodecyl sulfate
SDWA	Safe Drinking Water Act
SV-40	Simian virus 40
TA	Transcriptional activation
TIF	Transcriptional intermediary factors
tk	thymidine kinase
Tris	Tris(hydroxymethyl)aminomethane
TSCA	Toxic Substances Control Act
WWF	World Wildlife Fund

ACKNOWLEDGEMENTS

*The following individuals are acknowledged for their contributions to the
In Vitro Endocrine Disruptor Screening Assay review process:*

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Endocrine Disruptor Working Group (EDWG)

Agency for Toxic Substances and Disease Registry (ATSDR)

Stephanie Miles-Richardson, Ph.D.

Consumer Product Safety Commission (CPSC)

Marilyn Wind, Ph.D. (EDWG, Co-Chair)

Department of the Interior (DOI)

Timothy Gross, Ph.D.

Environmental Protection Agency (U.S. EPA)

Angela Auletta, Ph.D.
Karen Hamernik, Ph.D.
Richard Hill, M.D., Ph.D.
Sally Perreault Darney, Ph.D.

Food and Drug Administration (FDA)

Michael Bolger, Ph.D., D.A.B.T.
Paul Brown, Ph.D.
Kenneth Delclos, Ph.D.
Charles Eirkson, M.S.

FDA (cont'd)

Suzanne Fitzpatrick, Ph.D., D.A.B.T.
David Hattan, Ph.D. (EDWG, Co-Chair)
Abigail Jacobs, Ph.D.
Alexander Jordan, Ph.D.
David Morse, Ph.D.
Melvin Stratmeyer, Ph.D.
Thomas Umbreit, Ph.D.

National Institute for Occupational Safety & Health (NIOSH)

Eisuke Murono, Ph.D.

National Institute of Environmental Health Sciences (NIEHS)

Jerry Heindel, Ph.D.
Retha Newbold, M.A.
William Stokes, D.V.M., D.A.C.L.A.M.
(Executive Director, ICCVAM)
Julius Thigpen, Ph.D.

Occupational Safety and Health Administration (OSHA)

Surender Ahir, Ph.D.

National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

Bradley Blackard, M.S.P.H.
ILS, Inc.

Sue Brenzel
ILS, Inc.

Loretta Frye
NIEHS

Christina Inhof, M.S.P.H.
ILS, Inc.

Linda Litchfield
ILS, Inc.

Deborah McCarley
NIEHS

Steven Myers
ILS, Inc.

Michael Paris
ILS, Inc.

Barbara Shane, Ph.D., D.A.B.T.
ILS, Inc.

**William Stokes, D.V.M., Diplomate,
ACLAM (Director)**
NIEHS

Judy Strickland, Ph.D., D.A.B.T.
ILS, Inc.

Raymond Tice, Ph.D.
ILS, Inc.

Errol Zeiger, Ph.D., J.D.
ILS, Inc./Zeiger Consulting

**Additional Reviewers for the *In Vitro* Endocrine Disruptor Screening Assay
Background Review Documents (BRD)**

Emily Askew

University of North Carolina

Neepa Choksi, Ph.D.

NIEHS

Ralph Cooper, Ph.D.

U.S. EPA

L. Earl Gray, Ph.D.

U.S. EPA

Susan Laws, Ph.D.

U.S. EPA

Gary Timm, M.S., M.A.

U.S. EPA

Vickie Wilson, Ph.D.

U.S. EPA